JERUSALEM, Israel, July 7, 2010 /PRNewswire-FirstCall/ —
Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a
developer of oral delivery systems, today announced that Oramed
entered into a Manufacturing Supply Agreement (MSA) with
sanofi-aventis. According to the MSA, sanofi-aventis will supply
Oramed with specified quantities of recombinant human insulin to be
used by Oramed for its clinical trials in the USA.
The MSA is managed by the Commercial and External Partnership
within Industrial Affairs (CEPiA) at sanofi-aventis, which will
allow Oramed to leverage sanofi-aventis’ ability and expertise
regarding quality and regulatory support.
“Oramed’s oral delivery technology together with sanofi-aventis
capabilities to produce insulin on a large scale supports Oramed’s
efforts to conduct clinical development of Oramed’s oral insulin
capsule in the growing diabetes market in the US.”, says Nadav Kidron, Oramed’s CEO. “It is very
satisfying to work with such a professional company and their
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of
oral delivery solutions for drugs and vaccines presently delivered
via injection. Oramed is seeking to revolutionize the treatment of
diabetes through its patented flagship product, an orally
ingestible insulin capsule currently in phase 2 clinical trials.
Established in 2006, Oramed’s technology is based on over 25 years
of research by top research